周三盘后，医疗器械公司PROCEPT BioRobotics（股票代码：PRCT）股价大幅下挫8.08%，尽管公司公布的季度业绩优于分析师预期。这一显著跌幅引发了投资者对公司未来发展前景的担忧。
根据PROCEPT BioRobotics发布的最新财报，截至6月30日的季度调整后每股亏损为0.35美元，优于分析师平均预期的0.41美元亏损。公司季度营收达到7918万美元，同比增长48.4%，同样超出市场预期的7640万美元。尽管业绩表现优于预期，但公司仍录得1958万美元的季度亏损，这可能是导致股价下跌的主要原因之一。
值得注意的是，PROCEPT BioRobotics股价今年以来已下跌40.2%，本季度alone下跌16.5%。这反映出投资者对公司持续亏损的担忧，尽管其收入增长强劲。另一方面，分析师们对公司前景仍保持乐观，平均评级为"买入"，12个月目标价中位数为77.50美元，较当前股价有显著上涨空间。然而，盘后的大幅跌幅表明，市场可能需要看到更多盈利改善的迹象，才能恢复对PROCEPT BioRobotics的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.